Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
How efficacious is SHINGRIX?
SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.1,2,4,5
Meet
Jennifer*
She feels healthy, but she’s still at risk.1-3
Who are the people in Jennifer’s life?
- Her husband and 2 children in high school
- The employees in her flower shop
- Her running buddies
Lifestyle:
She eats healthily, walks every day, and runs a few times a week
Medical history:
No current medical issues
Interaction with HCP:
Diligent about annual health check ups, and is proactive in discussing lifestyle changes to help keep herself healthy
Recommendation opportunity:
When she is scheduling her annual flu jab
*Not an actual patient
Meet Luis*
He prioritises taking care of others over himself.
Who are the people in Luis' life?
- His wife, 3 children, and parents who live with him
- The team at his software development company
- His parents, who are not as healthy as they once were
Lifestyle:
He does not eat a healthy diet and is usually too busy to exercise
Medical history:
Type 2 diabetes
Interaction with HCP:
Reluctant about visiting the doctor and only goes a few times a year to review HbA1C levels
Recommendation opportunity:
Whilst collecting his repeat prescription
*Not an actual patient
Meet Richard*
He is getting older, but shingles prevention is not top of mind.3
Who are the people in Richard’s life?
- His wife and his daughter, who is a doctor
- His students and faculty at the university where he works
- His grandchildren whom he visits at least once a week
Lifestyle:
He doesn’t exercise enough and has become less mobile with age
Medical history:
Cardiovascular (CV) disease
Interaction with HCP:
Leans too much on daughter for medical advice
Recommendation opportunity:
Whilst collecting his repeat prescription
Note: Richard is eligible for a shingles vaccine via the National Immunisation Programme and should discuss this option with his GP or practice nurse.
*Not an actual patient
Meet Betty*
With so much to manage in relation to her health, she’s not thinking about shingles.3
Who are the people in Betty’s life?
- Her 4 children and 8 grandchildren
- Her close circle of friends nearby
Lifestyle:
She walks in the park when she can, and maintains a healthy diet to help manage her cholesterol
Medical history:
Gout, high cholesterol, macular degeneration, hypertension
Interaction with HCP:
Overwhelmed with seeing multiple specialists, she doesn’t always keep up with GP visits
Recommendation opportunity:
During a scheduled health check
Note: Betty is eligible for a shingles vaccine via the National Immunisation Programme and should discuss her options with her GP or practice nurse.
*Not an actual patient
More information on SHINGRIX
References
- Shingrix, GB Summary of Product Characteristics (SPC)
- Shingrix, NI Summary of Product Characteristics (SPC)
- Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
- Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
- Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32 (15):1745-53.
- Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8):1280-90.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
PM-GB-SGX-WCNT-210008
Date of preparation: July 2021
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
